Page 2,678«..1020..2,6772,6782,6792,680..2,6902,700..»

Stem Cell Blowback from Proposition 71

Posted: August 5, 2012 at 3:51 pm


Proposition 71 last week once again
stood in the way of action by the $3 billion California stem cell
agency.

This time it was a bit of minutia
embedded in state law that prevented the agency's governing board
from going forward. The result is that the board will have to hold
another meeting in August to approve matters that need to be acted on
in a timely fashion.
The minutia involves the supermajority
quorum requirement for the board, the percentage of board members
needed to conduct business legally. Proposition 71, the 10,000-word
ballot initiative that created the agency in 2004, stipulates that 65
percent of the 29 members of the board be present for action.
Here is what happened: Late last
Thursday afternoon, CIRM directors were moving fast after a long day
of dealing with $151 million in research awards. But as they
attempted to act on proposed changes in the agency's important
intellectual property rules, one of the board members left the
meeting, presumably to catch a flight. The result was that the
meeting quickly ended after it was decided to deal with the IP
proposal and another matter during a telephonic meeting this month.
The quorum problem has plagued the CIRM
board since its inception, although the situation has eased since
J.T. Thomas
, a Los Angeles bond financier, was elected chairman in
2011. A few years back, the board also changed its rules to allow a
limited number of board members to participate in meetings by
telephone, reducing the pressure on board members to physically
attend meetings.
The obvious solution would be to change
the quorum to 50 percent, a reasonable standard. However, the board
is legally barred from doing that. To make the change would require a super, supermajority vote, 70 percent of
each house of the state legislature and the signature of the
governor. That is another bit that is embedded in state law, courtesy of Proposition 71. To attempt to win a  70 percent legislative vote would involve a political process
that could be contentious and also involve some horse-trading that
the stem cell agency would not like to see.
Why does the 65-percent quorum
requirement exist? Normally, one would think such internal matters
are best left to the governing board itself. It is difficult to know
why former CIRM Chairman Bob Klein and his associates wrote that
requirement into law. But it does allow a minority to have effective
veto power over many actions by the governing board.
Of course, there is another way to look
at the problem: CIRM board members could change their flights and
stick around until all the business is done. But that would ignore
the reality that all of them are extremely busy people and have
schedules that are more than full.
All of this goes to one of the major policy issues in California -- ballot box budgeting and the use of initiatives that are inflexible and all but impossible to change, even when the state is in the midst of a financial crisis in which the poor, the elderly and school children are the victims. One California economist has called the situation "our special hell."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Stem Cell Blowback from Proposition 71

$20 Million in Stem Cell Irony

Posted: August 5, 2012 at 3:51 pm


A bit of irony popped up this
week in the wake of approval of $151 million in awards by the
California stem cell agency.

One of the awards was $20 million to
StemCells, Inc., of Newark, Ca., which is also fighting hard for
another $20 million from the state research enterprise.
However, back in 2008, Kenneth
Stratton
, general counsel for the firm, put some distance between his
company and the agency, which is handing out $3 billion in toto.
Stratton said,

"We will take CIRM money last. We
don't want to be in a position where, years from now, we are actually
forced to sell [our products] in California at a loss."

But last week, Martin McGlynn, CEO of
StemCells, said in a press release,

“We are extremely grateful to CIRM
for its support.”

Times have changed for both the company
and CIRM, which is in the process of altering the intellectual
property rules that offended Stratton in 2008. The changes were due
to be approved last Thursday, but action was put off by the CIRM
board. It was overwhelmed as it dealt with the record pace of appeals
by researchers who were scrambling to overturn negative decisions by
grant reviewers.
StemCells' application for another $20
million is one of those being appealed. The board will take it up
again in either September or late October, after it undergoes
additional scrutiny by the agency.
CIRM is touting its IP changes as being
more friendly to business. They also can be made retroactive to cover
awards to business made in the past. CIRM directors expect to meet by
telephone, probably in August, to approve the new IP rules.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on $20 Million in Stem Cell Irony

Fears over 'stem cell tourism' Save

Posted: August 5, 2012 at 3:10 pm

Aug. 5, 2012, 3 a.m.

A GROWING number of overseas clinics touting stem cell therapy for conditions ranging from sexual disorders to HIV are targeting Australia, where such treatments are restricted.

Australian scientists have raised concerns about so-called ''stem cell tourism'', saying many of the treatments offered are unproven, untested and potentially deadly.

The Swiss firm Fetal Cell Technologies International has been advertising in Australia since last year and Emcell, based in Ukraine, started promoting its services last month.

It is estimated as many as 200 Australians have travelled overseas for the therapy. The secretary for science policy at the Australian Academy of Science, Bob Williamson, said he empathised with the desperation of seriously ill people but warned against the unproven therapies, which can cost up to $60,000.

''The therapies are almost all untested and unproven and sometimes they have killed people,'' Professor Williamson said. The Sun-Herald's calls to Emcell's Melbourne office were not returned.

Stem Cells Australia's Megan Munsie, who is conducting a study into stem cell tourism with Monash University, said many people she interviewed were unaware of the risks of therapy overseas.

''We're not talking about rubbing something into your skin or taking a capsule, we are talking about often a very invasive procedure,'' she said.

Link:
Fears over 'stem cell tourism' Save

Posted in Stem Cell Therapy | Comments Off on Fears over 'stem cell tourism' Save

Fears over ‘stem cell tourism’ Save

Posted: August 5, 2012 at 2:13 am

Aug. 5, 2012, 3 a.m.

A GROWING number of overseas clinics touting stem cell therapy for conditions ranging from sexual disorders to HIV are targeting Australia, where such treatments are restricted.

Australian scientists have raised concerns about so-called ''stem cell tourism'', saying many of the treatments offered are unproven, untested and potentially deadly.

The Swiss firm Fetal Cell Technologies International has been advertising in Australia since last year and Emcell, based in Ukraine, started promoting its services last month.

It is estimated as many as 200 Australians have travelled overseas for the therapy. The secretary for science policy at the Australian Academy of Science, Bob Williamson, said he empathised with the desperation of seriously ill people but warned against the unproven therapies, which can cost up to $60,000.

''The therapies are almost all untested and unproven and sometimes they have killed people,'' Professor Williamson said. The Sun-Herald's calls to Emcell's Melbourne office were not returned.

Stem Cells Australia's Megan Munsie, who is conducting a study into stem cell tourism with Monash University, said many people she interviewed were unaware of the risks of therapy overseas.

''We're not talking about rubbing something into your skin or taking a capsule, we are talking about often a very invasive procedure,'' she said.

Continue reading here:
Fears over 'stem cell tourism' Save

Posted in Stem Cell Therapy | Comments Off on Fears over ‘stem cell tourism’ Save

Embryonic blood vessels that make blood stem cells can also make beating heart muscles

Posted: August 4, 2012 at 5:13 pm

ScienceDaily (Aug. 2, 2012) UCLA stem cell researchers have found for the first time a surprising and unexpected plasticity in the embryonic endothelium, the place where blood stem cells are made in early development.

Scientists found that the lack of one transcription factor, a type of gene that controls cell fate by regulating other genes, allows the precursors that normally generate blood stem and progenitor cells in blood forming tissues to become something very unexpected -- beating cardiomyocytes, or heart muscle cells.

The finding is important because it suggests that the endothelium can serve as a source of heart muscle cells. The finding may provide new understanding of how to make cardiac stem cells for use in regenerative medicine, said study senior author Dr. Hanna Mikkola, an associate professor of molecular, cell and developmental biology in Life Sciences and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

"It was absolutely unbelievable. These findings went beyond anything that we could have imagined," Mikkola said. "The microenvironment in the embryonic vasculature that normally gives rise to blood cells can generate cardiac cells when only one factor, Scl, is removed, essentially converting a hematopoietic organ into a cardiogenic organ."

The two-year study is published Aug. 3, 2012 in the peer-reviewed journal Cell.

The findings were so surprising, in fact, that Mikkola and her team did not want to believe the results until all subsequent assays proved the finding to be true, said Amelie Montel-Hagen, study co-first author and a post-doctoral fellow.

"To make sure we had not switched the samples between blood forming tissues and the heart we ran the experiments again and repeatedly got the same results," Montel-Hagen said. "It turns out Scl acts as a conductor in the orchestra, telling the other genes in the endothelium who should be playing and who shouldn't be playing."

The team used microarray technology to determine which genes were "playing" in embryonic endothelium to generate blood stem and progenitor cells and found that in the absence of Scl, the genes required for making cardiomyocytes were activated instead, said study co-first author Ben Van Handel, a post-doctoral fellow.

The lone difference was that Scl was missing in the process that resulted in the fate switch between blood and heart.

"Scl has a known role as a master regulator of blood development and when we removed it from the equation, no blood cells were made," Van Handel said. "That the removal of Scl resulted in fully functional cardiomyocytes in blood forming tissues was unprecedented."

Read more from the original source:
Embryonic blood vessels that make blood stem cells can also make beating heart muscles

Posted in Stem Cell Videos | Comments Off on Embryonic blood vessels that make blood stem cells can also make beating heart muscles

Scientists Work To Develop Human Organs From Stem Cells

Posted: August 4, 2012 at 5:13 pm

(Credit: ANNE-CHRISTINE POUJOULAT/AFP/Getty Images)

By Michelle Durham

PHILADELPHIA (CBS) - Scientists at the University of Pennsylvania have teamed up with their counterparts all over the world, working to develop human organs from the stem cells of the patient.

Using a 3-D printer, and other tools, their goal is to eradicate the risk of rejection by building organs that wont require the immunosuppressant drugs current patients have to take.

Professor of Innovation in the Department of Bioengineering at the University of Pennsylvania, Dr. Christopher Chen says he and his colleagues have been working hard on using stem cells to engineer tissues.

One of the big limitations for being able to assemble the cells into larger structures such as hearts or livers [is that] once you form a tissue that is larger then a certain size all the cells in the center of that block will starve because they are not getting access to oxygen or blood, explains Dr. Chen.

Postdoctoral fellow Jordan Miller who works with Chen saw an exhibit featuring donated human organs filled with silicone so Miller wondered if he could create the pathways for the blood flow first and then build the organs around it.

Right now they can make pathways the size of a pinky, but Chen and Miller hope that in 10 years time the technology will be advanced enough to create an organ from these gels in their lab.

But it will be many more years before they can be transplanted into a patient.

Read more:
Scientists Work To Develop Human Organs From Stem Cells

Posted in Stem Cell Videos | Comments Off on Scientists Work To Develop Human Organs From Stem Cells

Embryonic blood vessels that make blood stem cells can also make beating heart muscles

Posted: August 4, 2012 at 4:13 pm

ScienceDaily (Aug. 2, 2012) UCLA stem cell researchers have found for the first time a surprising and unexpected plasticity in the embryonic endothelium, the place where blood stem cells are made in early development.

Scientists found that the lack of one transcription factor, a type of gene that controls cell fate by regulating other genes, allows the precursors that normally generate blood stem and progenitor cells in blood forming tissues to become something very unexpected -- beating cardiomyocytes, or heart muscle cells.

The finding is important because it suggests that the endothelium can serve as a source of heart muscle cells. The finding may provide new understanding of how to make cardiac stem cells for use in regenerative medicine, said study senior author Dr. Hanna Mikkola, an associate professor of molecular, cell and developmental biology in Life Sciences and a researcher with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

"It was absolutely unbelievable. These findings went beyond anything that we could have imagined," Mikkola said. "The microenvironment in the embryonic vasculature that normally gives rise to blood cells can generate cardiac cells when only one factor, Scl, is removed, essentially converting a hematopoietic organ into a cardiogenic organ."

The two-year study is published Aug. 3, 2012 in the peer-reviewed journal Cell.

The findings were so surprising, in fact, that Mikkola and her team did not want to believe the results until all subsequent assays proved the finding to be true, said Amelie Montel-Hagen, study co-first author and a post-doctoral fellow.

"To make sure we had not switched the samples between blood forming tissues and the heart we ran the experiments again and repeatedly got the same results," Montel-Hagen said. "It turns out Scl acts as a conductor in the orchestra, telling the other genes in the endothelium who should be playing and who shouldn't be playing."

The team used microarray technology to determine which genes were "playing" in embryonic endothelium to generate blood stem and progenitor cells and found that in the absence of Scl, the genes required for making cardiomyocytes were activated instead, said study co-first author Ben Van Handel, a post-doctoral fellow.

The lone difference was that Scl was missing in the process that resulted in the fate switch between blood and heart.

"Scl has a known role as a master regulator of blood development and when we removed it from the equation, no blood cells were made," Van Handel said. "That the removal of Scl resulted in fully functional cardiomyocytes in blood forming tissues was unprecedented."

Here is the original post:
Embryonic blood vessels that make blood stem cells can also make beating heart muscles

Posted in Stem Cells | Comments Off on Embryonic blood vessels that make blood stem cells can also make beating heart muscles

Scientists Work To Develop Human Organs From Stem Cells

Posted: August 4, 2012 at 4:13 pm

(Credit: ANNE-CHRISTINE POUJOULAT/AFP/Getty Images)

By Michelle Durham

PHILADELPHIA (CBS) - Scientists at the University of Pennsylvania have teamed up with their counterparts all over the world, working to develop human organs from the stem cells of the patient.

Using a 3-D printer, and other tools, their goal is to eradicate the risk of rejection by building organs that wont require the immunosuppressant drugs current patients have to take.

Professor of Innovation in the Department of Bioengineering at the University of Pennsylvania, Dr. Christopher Chen says he and his colleagues have been working hard on using stem cells to engineer tissues.

One of the big limitations for being able to assemble the cells into larger structures such as hearts or livers [is that] once you form a tissue that is larger then a certain size all the cells in the center of that block will starve because they are not getting access to oxygen or blood, explains Dr. Chen.

Postdoctoral fellow Jordan Miller who works with Chen saw an exhibit featuring donated human organs filled with silicone so Miller wondered if he could create the pathways for the blood flow first and then build the organs around it.

Right now they can make pathways the size of a pinky, but Chen and Miller hope that in 10 years time the technology will be advanced enough to create an organ from these gels in their lab.

But it will be many more years before they can be transplanted into a patient.

The rest is here:
Scientists Work To Develop Human Organs From Stem Cells

Posted in Stem Cells | Comments Off on Scientists Work To Develop Human Organs From Stem Cells

Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as Biotech Industry Thrives in 2012

Posted: August 4, 2012 at 4:12 pm

NEW YORK, NY--(Marketwire -08/03/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) are both up 31 percent for the year, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Osiris Therapeutics, Inc. (OSIR) and Pluristem Therapeutics Inc. (PSTI).

Access to the full company reports can be found at: http://www.ParagonReport.com/OSIR http://www.ParagonReport.com/PSTI

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Osiris Therapeutics is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris' stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation.

Pluristem Therapeutics is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic disease. Shares of the company have gained 40 percent in the last month.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Go here to read the rest:
Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as Biotech Industry Thrives in 2012

Posted in Biotechnology | Comments Off on Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as Biotech Industry Thrives in 2012

Fears over ‘stem cell tourism’

Posted: August 4, 2012 at 4:12 pm

A GROWING number of overseas clinics touting stem cell therapy for conditions ranging from sexual disorders to HIV are targeting Australia, where such treatments are restricted.

Australian scientists have raised concerns about so-called ''stem cell tourism'', saying many of the treatments offered are unproven, untested and potentially deadly.

The Swiss firm Fetal Cell Technologies International has been advertising in Australia since last year and Emcell, based in Ukraine, started promoting its services last month.

It is estimated as many as 200 Australians have travelled overseas for the therapy. The secretary for science policy at the Australian Academy of Science, Bob Williamson, said he empathised with the desperation of seriously ill people but warned against the unproven therapies, which can cost up to $60,000.

Advertisement

''The therapies are almost all untested and unproven and sometimes they have killed people,'' Professor Williamson said. The Sun-Herald's calls to Emcell's Melbourne office were not returned.

Stem Cells Australia's Megan Munsie, who is conducting a study into stem cell tourism with Monash University, said many people she interviewed were unaware of the risks of therapy overseas.

''We're not talking about rubbing something into your skin or taking a capsule, we are talking about often a very invasive procedure,'' she said.

See more here:
Fears over 'stem cell tourism'

Posted in Cell Therapy | Comments Off on Fears over ‘stem cell tourism’

Page 2,678«..1020..2,6772,6782,6792,680..2,6902,700..»